Enhanced vs. Basic Software Documentation Level in AI/ML SaMD: An Audit of 687 Post-2023 FDA Clearances An audit of all 687 AI/ML software-as-a-medical-device 510(k) and De Novo authorizations cleared after FDA's June 14, 2023 final guidance found that among the 107 authorizations (15.6%) that explicitly name a documentation level, 80 (74.8%) cleared at Basic Documentation Level and 27 (25.2%) at Enhanced, according to the analysis published via the FDA Device Explorer with data as of November 17, 2026. Radiology excluding radiation-therapy contouring cleared at Basic in 56 of 65 cases (86.2%), Radiology CADe/CADx/CADt clearances at 19 of 20 (95.0%), authorizations with a Predetermined Change Control Plan at 13 of 16 (81.3%), and De Novos naming a level at 4 of 6 (66.7%). The audit concludes that AI/ML use, a PCCP, or a De Novo pathway does not automatically trigger FDA's Enhanced Documentation Level, which adds a Software Design Specification and deeper verification traceability that can add months of documentation work. Download the 1-Page Regulatory Landscape Brief: Get the printable, self-updating Enhanced vs. Basic Documentation Level in AI/ML SaMD PDF https://innolitics.com/pdf/enhanced-vs-basic-documentation-level-ai-samd.pdf with clickable highlight links to every cited FDA summary and guidance passage. Many AI medical device teams assume that using machine learning, filing a Predetermined Change Control Plan PCCP , or pursuing a De Novo classification automatically pushes their submission into FDA’s Enhanced Documentation Level . This article tests that assumption against every AI/ML software as a medical device SaMD 510 k and De Novo authorization decided after FDA issued its June 14, 2023 final guidance, Content of Premarket Submissions for Device Software Functions . Using the FDA Device Explorer https://fda.innolitics.com/ data as of November 17, 2026; latest decision date November 15, 2026 , we audited all 687 post-guidance AI/ML SaMD authorizations. Because FDA does not require sponsors to state software documentation level in a public 510 k Summary, 107 authorizations 15.6% explicitly name Basic or Enhanced Documentation Level under the 2023 framework while 75 still cite the legacy 2005 Level of Concern terminology . Among those 107 authorizations, 80 74.8% cleared at Basic Documentation Level and 27 25.2% cleared at Enhanced Documentation Level . In Radiology excluding radiation-therapy contouring, 56 of 65 86.2% cleared at Basic . Across Radiology CADe, CADx, and CADt clearances QAS , QFM , QDQ , QBS , MYN , POK , 19 of 20 95.0% cleared at Basic . Among AI/ML SaMD authorizations with a PCCP, 13 of 16 81.3% cleared at Basic . Among AI/ML SaMD De Novos naming a level, 4 of 6 66.7% cleared at Basic , including 2 of 2 100% in Radiology . Every one of the 27 Enhanced authorizations maps cleanly to five concrete categories: radiation therapy contouring 7 , Siemens Healthineers non-RT boilerplate templates 7 , high-acuity cardiovascular and critical-care sepsis tools 7 , autonomous diabetic retinopathy diagnostics 2 , and intraoperative orthopedic guidance, digital contraception, or an enterprise imaging suite 4 . On June 14, 2023, FDA replaced its 2005 three-tier Level of Concern model Minor, Moderate, Major with a two-tier Documentation Level framework in Content of Premarket Submissions for Device Software Functions https://fda.innolitics.com/h/8aPs6gLNBjH4 . The guidance draws a single bright line based on risk evaluated prior to implementing risk controls : Enhanced Documentation adds meaningful software engineering overhead compared to Basic, including a Software Design Specification SDS , more detailed risk management and verification traceability, and deeper architecture documentation. Over-classifying a Basic device as Enhanced can add months of unnecessary documentation work before filing. Crucially, the guidance does not treat AI/ML algorithms, PCCPs, or De Novo submissions as automatic triggers for Enhanced Documentation. Instead, Appendix examples illustrate the boundary: We pulled the complete cohort of FDA medical device authorizations in the FDA Device Explorer https://fda.innolitics.com/ matching contains ai ml = true , is samd = true , and decision date = 2023-06-14 through November 15, 2026 data as of November 17, 2026, queried November 22, 2026 . That yields 687 authorizations 539 in Radiology, 148 across 12 other review panels, and 16 De Novos , all with public PDFs. A naive exact search for "Basic Documentation" and "Enhanced Documentation" misses real clearances that write "Basic" Level of Concern , 'Enhanced' software documentation , Documentation Level: Basic , Level of documentation: Enhanced , or place the level in a comparison table cell. It can also double-count summaries that mention both terms in a footnote explaining the 2023 transition such as K252204 , which is Basic . To avoid both failure modes, we fetched full OCR text for 357 of the 687 records : every post-June 14, 2023 AI/ML SaMD authorization containing the word "Basic" , "Enhanced" , "Documentation Level" , or the 2023 guidance title, plus all 16 De Novos reading FDA Decision Summaries where 510 k summaries are not published, such as digital pathology 510 k K254115 https://fda.innolitics.com/h/lnpCyra7999I . Every candidate passage was verified verbatim against the source PDF and linked via FDA Device Explorer native highlight links. Of 687 post-June 14, 2023 AI/ML SaMD authorizations, 107 explicitly name Basic or Enhanced Documentation Level . Another 75 summaries still reference the legacy 2005 Level of Concern wording for example, Moderate Level of Concern , and the remaining summaries omit documentation level altogether. | Cohort / Segment Jun 14, 2023 to Nov 15, 2026 | Naming a Level | Basic | Enhanced | % Basic | |---|---|---|---|---| | All AI/ML SaMD naming a 2023 level | 107 | 80 | 27 | 74.8% | | Radiology RA , all product codes | 72 | 56 | 16 | 77.8% | | Radiology RA , excluding RT contouring QKB , MUJ | 65 | 56 | 9 | 86.2% | | Radiology CADe / CADx / CADt QAS , QFM , QDQ , QBS , MYN , POK | 20 | 19 | 1 | 95.0% | | AI/ML SaMD with a PCCP | 16 | 13 | 3 | 81.3% | | AI/ML SaMD De Novos all review panels | 6 | 4 | 2 | 66.7% | | Radiology AI/ML SaMD De Novos | 2 | 2 | 0 | 100.0% | | Anesthesiology / Acoustic / Sleep AN | 9 | 9 | 0 | 100.0% | | Cardiovascular CV | 9 | 3 | 6 | 33.3% | | Radiology RT Contouring QKB , MUJ | 7 | 0 | 7 | 0.0% | | Ophthalmology Autonomous Retinal AI OP / PIB | 2 | 0 | 2 | 0.0% | In clinician-in-the-loop radiology detection, diagnosis, and triage, Basic Documentation Level is the overwhelming norm . Nineteen of 20 clearances across QAS , QFM , QDQ , QBS , MYN , and POK cleared at Basic, including high-profile triage and cancer screening products: MYN QBS QFM , Envisionit Radify Triage QAS QDQ , ScreenPoint Transpara POK The single Enhanced Radiology CADt in the entire cohort is Siemens Healthineers’s syngo.CT LVO Detection K243145, Apr 2025 https://fda.innolitics.com/h/9DNEQwKfnAJo , QAS , which uses the same Enhanced boilerplate language Siemens applied across six other non-RT syngo and nuclear-medicine filings. Sixteen AI/ML SaMD De Novos were granted after June 14, 2023. Four recent grants late 2025 through 2026 do not yet have published FDA decision summaries, three earlier grants still cited legacy 2005 Moderate Level of Concern, and three decision summaries omitted documentation level. Among the six AI/ML SaMD De Novos that name a 2023 documentation level , four 66.7% cleared at Basic : RA / SEZ : 5-year breast cancer risk prediction from screening mammograms SAO : opportunistic low bone mineral density screening on radiographs PA / SFH , with PCCP : digital pathology prognostic test EN / SHL : pediatric otoscopy detection aid Only two AI/ML SaMD De Novos cleared at Enhanced , and both sit squarely in acute, life-threatening clinical decision-making: Prenosis Sepsis ImmunoScore DEN230036, Apr 2024 https://fda.innolitics.com/h/CmD QMEEMi b , GU / SAK , whose FDA decision summary explicitly cites FDA’s June 2023 sepsis alarm example, and Powerful Medical Queen of Hearts DEN250044, Sep 2026 https://fda.innolitics.com/h/SqR0tJv8HiZb , CV / SHS , with PCCP , an acute coronary syndrome OMI ECG model. The same pattern holds for Predetermined Change Control Plans PCCPs . Across all 16 post-guidance AI/ML SaMD clearances with a PCCP that name a documentation level, 13 81.3% cleared at Basic , including ChestView US K252486 https://fda.innolitics.com/h/Ygskxgk8IXHk , ArteraAI Prostate DEN240068 https://fda.innolitics.com/h/2gtuh3Ixp0ZU , ArteraAI Breast K254115, May 2026 https://fda.innolitics.com/h/lnpCyra7999I , Apple’s Hypertension Notification Feature K250507, Sep 2025 https://fda.innolitics.com/h/Kd3m9mQY TkK and Sleep Apnea Notification Feature K240929, Sep 2024 https://fda.innolitics.com/h/SjQOBWqtKEWm . Rather than appearing randomly across AI products, every single one of the 27 Enhanced AI/ML SaMD authorizations falls into one of five concrete patterns. The alignment between FDA’s worked guidance examples and actual clearance outcomes is striking: QKB / MUJ is 7 of 7 Enhanced 100% . PIB is 2 of 2 Enhanced 100% . syngo and MI product lines, while Siemens itself cleared five other post-2023 AI SaMD products at Basic, including Before defaulting your software engineering team into Enhanced Documentation overhead, run a disciplined pre-mitigation hazard check against FDA’s June 2023 test: This audit relies on public FDA 510 k Summaries and De Novo Decision Summaries indexed in the FDA Device Explorer. Because FDA does not require a 510 k Summary to disclose software documentation level, only 107 of 687 post-June 14, 2023 AI/ML SaMD authorizations explicitly name Basic or Enhanced with another 75 citing legacy 2005 Level of Concern terminology and four recent AI SaMD De Novos awaiting publication of their FDA decision summaries . Reporting bias is possible if sponsors who clear at Basic or Enhanced disclose documentation level at different rates. In addition, documentation level is determined by each device’s specific pre-mitigation hazards and intended use, not by product code alone. Using AI/ML, adding a PCCP, or pursuing a De Novo classification does not automatically require Enhanced Software Documentation. Across all 107 post-June 14, 2023 AI/ML SaMD authorizations that name a documentation level, nearly three in four 74.8% cleared at Basic, rising to 86.2% in non-RT Radiology and 95.0% in Radiology CADe/CADx/CADt. Enhanced Documentation clusters sharply where software failure creates a direct, probable hazard of death or serious injury: radiation therapy contouring, acute cardiovascular and sepsis monitoring, autonomous diagnostics, intraoperative surgical guidance, and contraception. Source: FDA Device Explorer by Innolitics https://fda.innolitics.com/ , cohort of 687 AI/ML SaMD authorizations decided from June 14, 2023 through November 15, 2026 data as of November 17, 2026; retrieved November 22, 2026 . Download the companion 1-page printable summary: Enhanced vs. Basic Documentation Level in AI/ML SaMD PDF https://innolitics.com/pdf/enhanced-vs-basic-documentation-level-ai-samd.pdf .